Trial Profile
A phase II, single-arm trial of epratuzumab, an anti-CD22 humanized antibody, in patients with Waldenstrom's macroglobulinaemia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences; Immunomedics
- 05 Feb 2008 Status changed from in progress to dicontinued. Trial terminated due to low accrual.
- 02 Jan 2006 New trial record.